Keloid Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Keloid Treatment Market Trends and Insights

Rising Preference For Multimodal Keloid Therapy

The keloid treatment market is shifting from single-modality care as recurrence control becomes as critical as short-term lesion reduction. A 2026 systematic review assessing 162 studies found that treatment plans combining intralesional corticosteroids, surgical excision, laser modalities, and radiotherapy delivered stronger and more durable outcomes than single-modality approaches.^{[2]Masafumi Nakashima et al., “Genomic and Epigenetic Landscapes of Keloid Scarring: Ancestry-Dependent Insights and Therapeutic Implications,” Cosmetics, doi.org} This shift increases revenue per treated episode by distributing spending across drugs, procedures, and follow-up visits. A 2025 network meta-analysis reported that Triamcinolone acetonide (TAC) combined with 5-Fluorouracil and pulsed-dye laser achieved a relative risk of 2.98 compared with TAC monotherapy, supporting broader adoption of bundled treatment protocols.^{[3]Alicia R. Martin et al., “Multi-ancestry Meta-analysis of Keloids Uncovers Novel Susceptibility Loci in Diverse Populations,” Nature Communications, nature.com}

Expanding Use Of Intralesional Corticosteroid And 5-FU Combination

The keloid treatment market is benefiting from a clear shift toward corticosteroid and 5-Fluorouracil (5-FU) combinations in settings that support repeat injection protocols. A 2024 systematic review and meta-analysis covering 15 studies found that corticosteroid plus 5-FU delivered stronger patient and observer assessments, greater scar height reduction, and fewer adverse effects, such as hypopigmentation, skin atrophy, and telangiectasia, than corticosteroid-only treatment. This finding supports escalation from low-cost monotherapy to a regimen that improves visible outcomes and tolerability. It also creates a practical market split, with higher-resource clinics adopting combination care and cost-sensitive systems continuing to rely more heavily on steroid-only injections.

Growing Adoption Of Post-Excision Adjuvant Radiotherapy

The keloid treatment market is gaining momentum from the wider use of post-excision adjuvant radiotherapy for large or treatment-resistant lesions. A 2025 retrospective study published in BMC Surgery found that multimodal adjuvant therapy after surgical excision reduced recurrence more effectively than surgery alone. This approach gives clinics a stronger basis for long-term disease control and supports the referral of severe cases to procedural pathways. A March 2025 publication reported zero keloid recurrence across 16 keloids in 12 patients treated with surgical excision plus SRT-100 at Taiwan’s Tri-Service Military Hospital, strengthening the commercial case for superficial radiotherapy systems.

Increasing Availability Of Laser-Assisted Delivery And Advanced Equipment

The keloid treatment market is also receiving support from broader access to laser platforms and related device infrastructure. In December 2025, Sciton received US Food and Drug Administration (FDA) 510(k) clearance for its JOULE 1064nm System for the reduction of red pigmentation in keloid scars, showing that device makers are pursuing specific scar-related indications. In April 2026, Shanghai Apolo Medical Technology received FDA 510(k) clearance for its Picosecond Nd:YAG Laser Systems, signaling that new entrants are targeting regulated scar-treatment applications in the United States. These approvals shorten the path between clinical positioning and commercial adoption while supporting device-linked care as a visible growth engine in the keloid treatment market.

High Recurrence Rates After Monotherapy

High recurrence after single-modality treatment remains a key constraint in the keloid treatment market. A European cohort study (2025) of 206 patients found that patients treated with triamcinolone acetonide (TAC) injections and laser therapy had significantly higher recurrence rates, with TAC reporting χ² = 21.9 and p < 0.001. This limits confidence in low-intensity treatment pathways and increases the likelihood of patients moving through multiple regimens before achieving durable disease control. Repeat visits also reduce care delivery efficiency when they do not result in sustained outcome improvements. In lower-resource settings, where combination care remains less available, this creates a structural ceiling on therapeutic success within the keloid treatment market. Until providers adopt more consistent recurrence-control protocols, the market will continue to record uneven outcomes across regions and provider types.

Access Constraints For Radiation And Device-Based Care In Smaller Markets

The keloid treatment market faces major access constraints in regions with a high epidemiological burden but limited treatment infrastructure. A study from the Regional Hospital Center of Dosso in Niger (2026) reported that local treatment options were largely limited to corticosteroid infiltration and basic excision, while advanced modalities remained largely unavailable. This infrastructure gap limits the conversion of high disease burden into active market revenue. Advanced equipment, trained personnel, and financing channels remain critical to expanding access to higher-value care. Similar constraints affect smaller South American markets and rural parts of Asia, where affordability and practitioner availability continue to limit the penetration of radiation and device-based care. For manufacturers, market expansion will require clinical capacity building, not only product launches and distribution agreements.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type: Combination Protocols Eroding Corticosteroid Monotherapy Dominance

Intralesional corticosteroids held 28.12% of the keloid treatment market share in 2025, making them the largest treatment segment by revenue. Their position reflected strong clinical familiarity, low acquisition cost, and broad use across hospital and outpatient settings. The segment continues to benefit from established workflows, as clinicians can administer steroid injections without specialized capital equipment. However, the market is shifting away from steroid monotherapy as stronger clinical evidence supports combination regimens for longer-lasting disease control.

A 2025 network meta-analysis showed that combinations involving Triamcinolone acetonide (TAC), 5-Fluorouracil, and laser modalities outperformed monotherapy approaches, supporting protocol migration in high-volume centers. This shift explains why 5-Fluorouracil-based therapy is forecast to expand at the fastest CAGR of 5.53% through 2031 within this segment. Clinicians increasingly use it as the pharmacological backbone of combination regimens rather than only as an alternative injectable. Silicone-based therapy remains important for prevention-oriented use, especially after surgery and in patients for whom repeated injections are less suitable.

By Route of Administration: Device-Based Delivery Gaining Ground On Injectables

Injectable administration accounted for 46.45% of the keloid treatment market size by route of administration in 2025, keeping it the leading delivery channel. This position stemmed from the broad use of intralesional corticosteroids and 5-Fluorouracil in first-line and combination protocols. Injectable therapy aligns well with existing dermatology workflows and does not require the capital investment associated with laser or radiotherapy systems. This advantage keeps injectables central to the market, especially in regions that need familiar and scalable treatment options.

Procedural or device-based administration is projected to grow at a CAGR of 6.67% through 2031, making it the fastest-growing route in the keloid treatment market. Growth reflects demand for laser-assisted delivery, superficial radiotherapy, and cryotherapy systems that improve local tissue targeting while reducing reliance on repeated injections. Device-linked care can also lower dose intensity per session while still supporting visible response. As a result, the market is moving toward a more balanced route mix rather than remaining heavily injectable.

By End User: Dermatology Clinics Outpacing Hospital Growth As Care Migrates Outward

Hospitals held 38.66% of the keloid treatment market in 2025, keeping them the leading end-user category. Their share was supported by complex excision cases, adjuvant radiotherapy delivery, wound management needs, and the ability to coordinate multiple specialists for difficult lesions. Hospitals also remain important because they can manage cases that outpatient clinics are not equipped to handle. Severe lesions, recurrent disease, and post-surgical follow-up continue to create steady hospital-managed demand.

Dermatology clinics are expected to advance at the fastest CAGR of 7.35% through 2031, reflecting the growing role of outpatient care in the keloid treatment market. Providers can deliver intralesional injections, topical follow-up, laser procedures, and cryotherapy without inpatient admission. This improves patient convenience and supports adherence to repeat-session treatment. Shorter visits and lower service intensity also reduce patient drop-off between sessions.

Geography Analysis

North America is expected to account for 41.56% of the keloid treatment market share in 2025, making it the largest regional contributor. The United States is projected to drive this position through its strong dermatology infrastructure, broad procedural availability, and higher per-patient spending on specialist care. The region benefits from an established mix of pharmacological, laser-based, and adjuvant approaches, supporting broader treatment adoption across the care pathway. Canada also supports early commercialization of novel topical options, and BirchBioMed’s expected approval in Canada in February 2026 highlights the region’s role in differentiated product launches.

Asia-Pacific is expected to be the fastest-growing region, with the keloid treatment market size projected to increase at a CAGR of 8.56% through 2031. Elevated genetic susceptibility across several Asian populations, expanding private dermatology networks, and rising focus on scar appearance outcomes after surgery or injury support this growth. South Korea and Japan lead in technology adoption, while China adds scale through its large urban patient pool and expanding dermatology clinic chains. A 2025 multi-ancestry study expected to identify 26 susceptibility loci reinforces the region’s importance for targeted identification and treatment planning.

Europe is expected to hold the third-largest position in 2025, with Germany, the United Kingdom, France, Italy, and Spain contributing most of the regional revenue. The European keloid treatment market reflects a cautious treatment approach, supporting continued use of silicone-led and conservative management pathways. The Middle East and Africa remain underpenetrated despite a high underlying burden, mainly due to limited treatment infrastructure across several countries. South America shows steady growth, with larger countries gradually adopting combination care as dermatology services expand.